echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > NEJM: The blood vessels in the brain form a "sponge shape"?

    NEJM: The blood vessels in the brain form a "sponge shape"?

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cerebral Cavernous vascular tumors (CCM) system, a common central nervous system vascular malformations sporadic and hereditary diseases
    .


    This hemangioma is composed of vascular sinuses of varying sizes.


    Blood vessel

    Because CCM often has no abnormal vascular clusters during angiography, it is classified as an occult vascular malformation
    .


    In fact, the disease is not a real tumor, but a vascular malformation lacking arterial components


    The incidence in the population is estimated to be 0.


    Current studies have found that although familial CCMs are related to loss-of-function mutations in KRIT1 (CCM1), CCM2 or PDCD10 (CCM3), the genetic causes of sporadic CCMs that account for 80% of cases are still not fully understood
    .


    To this end, experts from the Department of Neurosurgery of the Sorbonne University, a public hospital in Paris, France, conducted a study, and the results were published in the journal NEJM


    The researchers used the prostaglandin D2 synthase (PGDS) promoter to create two mouse models that carry mutations found in human meningiomas
    .


    Targeted DNA sequencing was performed on the patient's surgically removed CCM, and the findings of the experiment were confirmed by droplet digital polymerase chain reaction analysis


    The researchers found that in mice expressing one of the two common genetic drivers of meningiomas in PGDS-positive cells-Pik3caH1047R or AKT1E17K, a typical lineage of CCMs (22% and 11% of mice, respectively) , Rather than meningioma, which prompted them to analyze tissue samples of sporadic CCMs from 88 patients
    .

    Mice expressing one of the two common genetic drivers of meningioma in PGDS-positive cells, Pik3caH1047R or AKT1E17K, will have a typical lineage of CCMs (22% and 11% of mice, respectively).
    In PGDS-positive cells In mice expressing one of the two common genetic drivers of meningiomas-Pik3caH1047R or AKT1E17K, a typical lineage of CCMs (22% and 11% of mice, respectively) appears.

    Researchers detected 39% and 1% of somatically activated PIK3CA and AKT1 mutations in the patient’s diseased tissues, respectively
    .


    Only 10% of the lesions carry mutations in the CCM gene


    Researchers detected 39% and 1% of somatically activated PIK3CA and AKT1 mutations in the patient’s diseased tissues, respectively


    It can be seen that in the tissue samples of sporadic CCM, there are more mutations in PIK3CA than in any other gene


    references:

    Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations.


    Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.